Patents by Inventor Keiichi Masuya
Keiichi Masuya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200291061Abstract: A method for producing a peptide by conducting steps (1) condensing an N-protected amino acid or an N-protected peptide to an N-terminus of a C-protected amino acid or a C-protected peptide represented by formula (II): wherein Y represents an amino acid or a peptide with an unprotected N-terminus; R1, R2 and R3 each independently represent an optionally substituted aliphatic hydrocarbon group, an optionally substituted aromatic hydrocarbon group, or —OR4 (wherein R4 represents an optionally substituted aliphatic or aromatic hydrocarbon group; two of R1, R2 and R3 may form a 5- to 7-membered ring together with the Si atom to which they are bonded; and the R1R2R3Si group has 8 or more carbon atoms and is bonded to a C-terminus of an amino acid or a peptide in Y, and (2) removing the protective group at the N-terminus of the peptide obtained in step (1).Type: ApplicationFiled: October 3, 2018Publication date: September 17, 2020Applicants: NISSAN CHEMICAL CORPORATION, PeptiDream Inc.Inventors: Akihiro NAGAYA, Michiharu HANDA, Naohiko YASUDA, Madoka YOSHINO, Yutaka KOBAYASHI, Keiichi MASUYA
-
Patent number: 10632187Abstract: Disclosed is a hemagglutinin-binding peptide producing an anti-influenza virus effect higher than that of existing peptides. Also disclosed are hemagglutinin-binding peptides comprising a polypeptide having any of the following amino acid sequences (i) to (iv): (i) Thr-MeGly-Asp-MePhe-MePhe-Ser-MeSer-His-Tyr-Thr-Val-Pro-Arg (SEQ ID NO: 1); (ii) Arg-Val-Ser-MePhe-Thr-Tyr-MePhe-MeSer-Tyr-Thr-Pro-Ser (SEQ ID NO: 2); (iii) an amino acid sequence with deletions, additions, or substitutions of one or several amino acids in SEQ ID NO: 1 or 2; and (iv) an amino acid sequence having 90% or more sequence identity to that of SEQ ID NO: 1 or 2.Type: GrantFiled: May 3, 2019Date of Patent: April 28, 2020Assignees: PeptiDream Inc., Tokyo Metropolitan Institute of Medical ScienceInventors: Kiichi Kubota, Patrick Reid, Michinori Kohara, Keiichi Masuya, Masaki Ohuchi
-
Publication number: 20190282688Abstract: Disclosed is a hemagglutinin-binding peptide producing an anti-influenza virus effect higher than that of existing peptides. Also disclosed are hemagglutinin-binding peptides comprising a polypeptide having any of the following amino acid sequences (i) to (iv): (i) Thr-MeGly-Asp-MePhe-MePhe-Ser-MeSer-His-Tyr-Thr-Val-Pro-Arg (SEQ ID NO: 1); (ii) Arg-Val-Ser-MePhe-Thr-Tyr-MePhe-MeSer-Tyr-Thr-Pro-Ser (SEQ ID NO: 2); (iii) an amino acid sequence with deletions, additions, or substitutions of one or several amino acids in SEQ ID NO: 1 or 2; and (iv) an amino acid sequence having 90% or more sequence identity to that of SEQ ID NO: 1 or 2.Type: ApplicationFiled: May 3, 2019Publication date: September 19, 2019Inventors: Kiichi Kubota, Patrick Reid, Michinori Kohara, Keiichi Masuya, Masaki Ohuchi
-
Patent number: 10328143Abstract: Object of the present invention is to provide a hemagglutinin-binding peptide producing an anti-influenza virus effect higher than that of existing peptides. The present invention provides, for example, a hemagglutinin-binding peptide comprising a polypeptide having any of the following amino acid sequences (i) to (iv): (i) Thr-MeGly-Asp-MePhe-MePhe-Ser-MeSer-His-Tyr-Thr-Val-Pro-Arg (SEQ ID NO: 1); (ii) Arg-Val-Ser-MePhe-Thr-Tyr-MePhe-MeSer-Tyr-Thr-Pro-Ser (SEQ ID NO: 2); (iii) an amino acid sequence with deletions, additions, or substitutions of one or several amino acids in SEQ ID NO: 1 or 2; and (iv) an amino acid sequence having 90% or more sequence identity to that of SEQ ID NO: 1 or 2.Type: GrantFiled: October 23, 2015Date of Patent: June 25, 2019Assignees: PeptiDream Inc., Tokyo Metropolitan Institute of Medical ScienceInventors: Kiichi Kubota, Patrick Reid, Michinori Kohara, Keiichi Masuya, Masaki Ohuchi
-
Publication number: 20170333549Abstract: Object of the present invention is to provide a hemagglutinin-binding peptide producing an anti-influenza virus effect higher than that of existing peptides. The present invention provides, for example, a hemagglutinin-binding peptide comprising a polypeptide having any of the following amino acid sequences (i) to (iv): (i) Thr-MeGly-Asp-MePhe-MePhe-Ser-MeSer-His-Tyr-Thr-Val-Pro-Arg (SEQ ID NO: 1); (ii) Arg-Val-Ser-MePhe-Thr-Tyr-MePhe-MeSer-Tyr-Thr-Pro-Ser (SEQ ID NO: 2); (iii) an amino acid sequence with deletions, additions, or substitutions of one or several amino acids in SEQ ID NO: 1 or 2; and (iv) an amino acid sequence having 90% or more sequence identity to that of SEQ ID NO: 1 or 2.Type: ApplicationFiled: October 23, 2015Publication date: November 23, 2017Inventors: Kiichi Kubota, Patrick Reid, Michinori Kohara, Keiichi Masuya, Masaki Ohuchi
-
Patent number: 9556180Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.Type: GrantFiled: January 21, 2014Date of Patent: January 31, 2017Assignee: Novartis AGInventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Robert Mah, Keiichi Masuya, Achim Schlapbach, Andrea Vaupel
-
Patent number: 9403827Abstract: The invention relates to compounds of formula (I): (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of as MDM2 and/or MDM4, and combinations comprising such compounds.Type: GrantFiled: January 21, 2014Date of Patent: August 2, 2016Assignee: NOVARTIS AGInventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Robert Mah, Keiichi Masuya, Achim Schlapbach, Andrea Vaupel
-
Patent number: 9365576Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.Type: GrantFiled: May 22, 2013Date of Patent: June 14, 2016Assignee: Novartis AGInventors: Simona Cotesta, Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Robert Mah, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
-
Publication number: 20150353563Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.Type: ApplicationFiled: January 21, 2014Publication date: December 10, 2015Inventors: Pascal FURET, Vito GUAGNANO, Philipp HOLZER, Joerg KALLEN, Robert MAH, Keiichi MASUYA, Achim SCHLAPBACH, Andrea VAUPEL
-
Publication number: 20150353551Abstract: The invention relates to compounds of formula (I): (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of as MDM2 and/or MDM4, and combinations comprising such compounds.Type: ApplicationFiled: January 21, 2014Publication date: December 10, 2015Applicant: NOVARTIS AGInventors: Pascal FURET, Vito GUAGNANO, Philipp HOLZER, Joerg KALLEN, Robert MAH, Keiichi MASUYA, Achim SCHLAPBACH, Andrea VAUPEL
-
Patent number: 9051279Abstract: The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH2 or N—R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.Type: GrantFiled: February 27, 2013Date of Patent: June 9, 2015Assignee: Novartis AGInventors: Joerg Berghausen, Nicole Buschmann, Pascal Furet, Francois Gessier, Joanna Hergovich Lisztwan, Philipp Holzer, Edgar Jacoby, Joerg Kallen, Keiichi Masuya, Carole Pissot Soldermann, Haixia Ren, Stefan Stutz
-
Patent number: 8969341Abstract: The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.Type: GrantFiled: November 28, 2012Date of Patent: March 3, 2015Assignee: Novartis AGInventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Robert Mah, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
-
Publication number: 20140350010Abstract: The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.Type: ApplicationFiled: November 28, 2012Publication date: November 27, 2014Applicant: NOVARTIS AGInventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Robert Mah, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
-
Publication number: 20140343084Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.Type: ApplicationFiled: July 10, 2014Publication date: November 20, 2014Inventors: Pascal FURET, Vito GUAGNANO, Philipp HOLZER, Joerg KALLEN, Lv LIAO, Robert MAH, Liang MAO, Keiichi MASUYA, Achim SCHLAPBACH, Stefan STUTZ, Andrea VAUPEL
-
Patent number: 8859535Abstract: The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.Type: GrantFiled: June 19, 2012Date of Patent: October 14, 2014Assignee: Novartis AGInventors: Nicole Buschmann, Pascal Furet, Philipp Holzer, Joerg Kallen, Keiichi Masuya, Stefan Stutz
-
Patent number: 8859586Abstract: The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.Type: GrantFiled: June 19, 2012Date of Patent: October 14, 2014Assignee: Novartis AGInventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Keiichi Masuya, Stefan Stutz
-
Publication number: 20140275158Abstract: The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.Type: ApplicationFiled: June 19, 2012Publication date: September 18, 2014Applicant: Novartis AGInventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Keiichi Masuya, Stefan Stutz
-
Patent number: 8815926Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.Type: GrantFiled: January 24, 2013Date of Patent: August 26, 2014Assignee: Novartis AGInventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Lv Liao, Robert Mah, Liang Mao, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
-
Publication number: 20140135306Abstract: The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.Type: ApplicationFiled: June 19, 2012Publication date: May 15, 2014Applicant: Novartis AGInventors: Nicole Buschmann, Pascal Furet, Philipp Holzer, Joerg Kallen, Keiichi Masuya, Stefan Stutz
-
Publication number: 20140011798Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.Type: ApplicationFiled: January 24, 2013Publication date: January 9, 2014Applicant: NOVARTIS AGInventors: Pascal FURET, Vito GUAGNANO, Philipp HOLZER, Joerg KALLEN, Lv LIAO, Robert MAH, Liang MAO, Keiichi MASUYA, Achim SCHLAPBACH, Stefan STUTZ, Andrea VAUPEL